Zkusit zdarma
Opthea Limited

Opthea Limited

OPT
Cena:
 
 
Valuace
100
Růst
33
Zdraví
75

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí

close

OPTHEA PROVIDES CORPORATE UPDATE

18-08-2025
SUCCESSFUL DFA SETTLEMENT REACHED COMPANY WITH CASH AND CASH EQUIVALENTS OF APPROXIMATELY USD20M DR ...

OPTHEA ANNOUNCES DECISION TO DISCONTINUE WET AMD TRIALS

31-03-2025
SHORE PHASE 3 TOPLINE RESULTS ACCELERATED; TRIAL DID NOT MEET PRIMARY ENDPOINT OF MEAN CHANGE IN BCV...

OPTHEA ANNOUNCES COAST PHASE 3 TRIAL TOPLINE RESULTS

24-03-2025
COAST PHASE 3 TRIAL FAILED TO MEET PRIMARY ENDPOINT OF MEAN CHANGE IN BCVA FROM BASELINE TO WEEK 52 ...

OPTHEA ANNOUNCES PHASE 2B WET AMD PUBLICATION

03-03-2025
BASELINE ANGIOGRAPHIC LESION CHARACTERISTICS PREDICTIVE OF CLINICAL RESPONSE PUBLISHED IN PEER-REVI...

OPTHEA TO PRESENT AT OPPENHEIMER HEALTHCARE CONFERENCE

07-02-2025
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., FEB. 07, 2025 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NASD...

OPTHEA WET AMD DATA FEATURED AT MACULA SOCIETY MEETING

06-02-2025
MELBOURNE, AUSTRALIA, AND PRINCETON, N.J., FEB. 06, 2025 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NAS...

OPTHEA TO HOST INVESTOR DAYS IN NEW YORK AND AUSTRALIA

08-01-2025
UPDATES ON COMMERCIAL INSIGHTS AND READINESS PLANS FOR SOZINIBERCEPT IN WET AMD OPTHEA MANAGEMENT TO...

OPTHEA TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

19-12-2024
BUSINESS UPDATE TO INCLUDE MASKED PHASE 3 PATIENT DEMOGRAPHICS AND BASELINE CHARACTERISTICS PRESENTA...

OPTHEA'S WET AMD PROGRAM TO BE FEATURED AT FLORETINA 2024

26-11-2024
MELBOURNE, AUSTRALIA, AND PRINCETON, N.J., NOV. 26, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NAS...

OPTHEA APPOINTS KATHY CONNELL TO BOARD OF DIRECTORS

15-11-2024
MS. CONNELL IS A COMMERCIAL EXECUTIVE WITH BUSINESS DEVELOPMENT EXPERTISE APPOINTMENT TAKES PLACE AS...

OPTHEA WET AMD PROGRAM TO BE PRESENTED AT INNOVATE RETINA

10-10-2024
MELBOURNE, AUSTRALIA, AND PRINCETON, N.J., OCT. 10, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NAS...

OPTHEA TO PARTICIPATE IN THE UBS VIRTUAL OPHTHALMOLOGY DAY 2024

30-09-2024
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., SEPT. 30, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NAS...

OPTHEA ANNOUNCES COMPLETION OF DRUG SUBSTANCE PPQ CAMPAIGN VALIDATING MANUFACTURING PROCESS OF SOZINIBERCEPT

18-09-2024
THREE CONSECUTIVE COMMERCIAL-SCALE BATCHES SUCCESSFULLY PRODUCED MAJOR MILESTONE FOR POTENTIAL BLA F...

OPTHEA TO HAVE SIGNIFICANT PRESENCE AT THE 24ᵗʰ EURETINA CONGRESS AND EURETINA INNOVATION SPOTLIGHT

10-09-2024
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., SEPT. 10, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NAS...

OPTHEA ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AND SENIOR HIRES

05-09-2024
DANIEL GEFFKEN APPOINTED CHIEF FINANCIAL OFFICER AD INTERIM MIKE CAMPBELL APPOINTED CHIEF COMMERCIAL...

OPTHEA TO PARTICIPATE IN H.C. WAINWRIGHT 26TH GLOBAL INVESTMENT CONFERENCE AND CANTOR 2024 GLOBAL HEALTHCARE CONFERENCE

03-09-2024
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., SEPT. 03, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NAS...

OPTHEA REPORTS FULL-YEAR FINANCIAL RESULTS AND BUSINESS UPDATES

30-08-2024
COMPLETED PATIENT ENROLLMENT IN COAST AND SHORE PIVOTAL WET AMD TRIALS FINANCINGS EXTENDED CASH RUNW...

OPTHEA TO PARTICIPATE IN THE H.C. WAINWRIGHT 4TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE, AUGUST 15, 2024

08-08-2024
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., AUG. 08, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NASD...

OPTHEA WELCOMES INTERNATIONAL RETINA THOUGHT LEADERS TO JOIN ITS MEDICAL ADVISORY BOARD

17-07-2024
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., JULY 17, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NASD...

OPTHEA ANNOUNCES RESULTS OF THE A$55.9M (US$36.9M¹) RETAIL ENTITLEMENT OFFER

14-07-2024
NEW SHARES UNDER THE RETAIL ENTITLEMENT OFFER AND NEW OPTIONS UNDER THE PLACEMENT AND ENTITLEMENT OF...

OPTHEA A$55.0M (US$36.9M¹) RETAIL ENTITLEMENT OFFER OPENS

18-06-2024
FULLY UNDERWRITTEN RETAIL ENTITLEMENT OFFER TO OPEN AT 9:00 AM (MELBOURNE TIME)  ON 19 JUNE 2024 RE...

OPTHEA SUCCESSFULLY COMPLETES PLACEMENT AND INSTITUTIONAL COMPONENT OF ENTITLEMENT OFFER RAISING A$171.5 MILLION (US$113.2M¹)

13-06-2024
FULLY UNDERWRITTEN RETAIL ENTITLEMENT OFFER TO RAISE A FURTHER APPROXIMATELY A$55.9M (US$36.9M 1 ) W...

OPTHEA ANNOUNCES PLACEMENT AND PARTIALLY UNDERWRITTEN ENTITLEMENT OFFER TO RAISE UP TO APPROXIMATELY A$227.3 MILLION (US$150.0 MILLION¹)

11-06-2024
FINANCING EXTENDS OPTHEA'S CASH RUNWAY THROUGH PHASE 3 TOPLINE DATA READOUT FOR BOTH PIVOTAL TRIALS ...

OPTHEA TO PRESENT AT CLINICAL TRIALS AT THE SUMMIT MEETING

03-06-2024
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., JUNE 03, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NASD...

OPTHEA COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 CLINICAL PROGRAM WITH SOZINIBERCEPT IN WET AMD

28-05-2024
PHASE 3 PROGRAM ENROLLED 1,984 PATIENTS ACROSS COAST AND SHORE TRIALS TRIALS DESIGNED TO REPLICATE S...

OPTHEA ANNOUNCES UPCOMING PRESENTATIONS AT THE RETINA WORLD CONGRESS 2024

01-05-2024
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., MAY 01, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NASDA...

OPTHEA TO PRESENT AT THE OIS RETINA INNOVATION SUMMIT AT ARVO

25-04-2024
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., APRIL 25, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NAS...

OPTHEA APPOINTS JOHN HAN, PHARMD, AS VP MEDICAL AFFAIRS

08-04-2024
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., APRIL 08, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NAS...

OPTHEA TO PARTICIPATE IN THE 23ʳᵈ ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

04-04-2024
MELBOURNE, AUSTRALIA AND PRINCETON, N.J., APRIL 04, 2024 (GLOBE NEWSWIRE) -- OPTHEA LIMITED (ASX/NAS...

OPTHEA APPOINTS SUJAL SHAH TO THE BOARD OF DIRECTORS

03-04-2024
FORMER CYMABAY THERAPEUTICS CEO BRINGS EXTENSIVE LEADERSHIP EXPERIENCE TO HIS ROLE AS A NON-EXECUTIV...

close

Dokumenty nejsou k dispozici

preloader